Oncology ABCs (part 2) Webinar – Vaccines: Niche no longer

Published on 12 October 2022

As a follow-on to Oncology ABCs (part 2) – Vaccines: Niche no longer, we spoke to two seasoned oncology experts to better understand the innovative technologies, recent trends and momentum in combination therapies. The most notable and recent catalysts are expected to continue to fuel advances and include heightened immunotherapy awareness, momentum in combination therapies (extending survival) and a drive for personalised medicine. We expect these recent trends and overall wider acceptance of complex vaccines to reinvigorate deal activity which targets companies with the most robust and innovative technologies.

Jens Bjørheim, Chief Medical Officer of Ultimovacs
Jeroen Rovers, Chief Medical Officer of Mendus (previously Immunicum)
Soo Romanoff, Managing Director – Healthcare, Head of Content, Edison Group

Share this with friends and colleagues